Hypothesis

Active suppression of autophagy in aging is driven not only by cell‑autonomous mechanisms (mTORC1, PKA, Rubicon, epigenetic silencing) but also by senescent‑cell‑derived extracellular vesicles (EVs) that deliver ceramide‑enriched microdomains to recipient cells. These ceramide platforms sequester the ULK1‑ATG13‑FIP200 initiation complex and promote PP2A‑mediated dephosphorylation of AMPK, thereby blocking autophagosome nucleation downstream of upstream stress signals.

Mechanistic Rationale

1. Senescent cells exhibit a SASP rich in EVs carrying neutral sphingomyelinase 2 (nSMase2) and sphingomyelin, as implied by the EV‑mediated systemic effects of young plasma [5] and the bidirectional autophagy‑senescence loop [4].
2. Ceramide generated by nSMase2 inserts into the plasma membrane and recruits PP2A, which dephosphorylates AMPKα at Thr172, reducing its activity.
3. Dephosphorylated AMPK fails to phosphorylate and activate ULK1, while ceramide‑rich domains also bind ATG14L, preventing its association with VPS34 complex, complementing the Rubicon‑mediated VPS34 inhibition described in [2]
4. The combined effect suppresses autophagosome initiation even when mTORC1 is transiently inhibited by fasting, explaining the diminishing returns of prolonged fasting in aged individuals.

Testable Predictions

• Prediction 1: EVs isolated from senescent human fibroblasts or aged mouse liver will show higher nSMase2 activity and ceramide content than EVs from young controls.
• Prediction 2: Treating aged mice with the nSMase2 inhibitor GW4869 (or with antibodies blocking EV uptake) during a 24‑h fast will restore hepatic LC3‑II turnover and decrease p62 levels to those seen in young fasted mice, despite unchanged mTORC1 activity.
• Prediction 3: In vitro, adding senescent‑cell EVs to young hepatocytes will diminish ULK1 phosphorylation (Ser555) and AMPK‑Thr172 phosphorylation, an effect rescued by PP2A inhibition (e.g., with okadaic acid low dose) or ceramide neutralization (using recombinant secreted sphingomyelinase).

Experimental Approach

1. EV isolation & characterization: Ultracentrifugation of plasma from young (3 mo) and aged (24 mo) mice; western blot for nSMase2, sphingomyelin, CD63; lipidomics for ceramide species.
2. In vivo treatment: Aged mice receive GW4869 (1 mg/kg i.p.) or vehicle every 12 h for 2 days preceding a 24‑h fast; controls include young mice +/- GW4869.
3. Readouts: Liver lysates assayed for LC3‑I/II conversion (with/without bafilomycin A1), p62, phospho‑AMPK (Thr172), phospho‑ULK1 (Ser555), and mTORC1 activity (p‑S6K).
4. In vitro validation: HepG2 cells treated with purified senescent‑cell EVs (± GW4869) under starvation; measure autophagy flux and signaling as above.

Potential Outcomes & Falsifiability

• If GW4869 or EV blockade fails to improve LC3‑II flux or phospho‑ULK1/AMPK levels in aged fasted mice, the hypothesis that ceramide‑laden EVs actively suppress autophagy is falsified.
• Conversely, a rescue of autophagy flux without altering mTORC1 phosphorylation would support the notion that a parallel, EV‑ceramide pathway acts downstream of nutrient sensors to inhibit the initiation complex.
• Demonstrating that young‑cell EVs lack ceramide enrichment and do not inhibit ULK1 would further strengthen the causal link.

This framework extends the current view of active autophagy suppression by adding a transmissible lipid‑signaling layer that integrates the SASP, vesicle biology, and lipid second messenger signaling, offering a distinct therapeutic target (nSMase2/EV uptake) to re‑sensitize aged cells to fasting‑induced autophagy.